DGAP-News

MOLOGEN AG: Successful capital increase enables phase III study with immunotherapy MGN 1703 (colon cancer) - Seite 2

offering of securities to be made in the United States of America will be
made by means of a prospectus that may be obtained from the issuer and that
will contain detailed information about the company and management, as well
as financial statements. There will be no public offer of the securities in
the United States of America. Subject to certain exceptions, the securities
referred to herein may not be offered or sold in Australia, Canada or Japan
or to, or for the account or benefit of, any national, resident or citizen
of Australia, Canada, Japan or South Africa.

This document is not for general publication, release or distribution in
the United Kingdom and may only be distributed in the United Kingdom to
persons who (i) are investment professionals falling within article 19 (5)
of the U.K. Financial Services and Markets Act 2000 (Financial Promotion)
Order 2005, in its current version (the 'Order'), or (ii) are high net
worth entities or other persons to whom it may lawfully be communicated
within the meaning of article 49 (2) (a) to (d) of the Order (all such
persons will be termed 'Relevant Persons' below). Anyone in the United
Kingdom who is not a Relevant Person may not act on the basis of this
notification release or its contents or rely thereon. Any investment or
investment activity to which this notification refers is only available to
Relevant Persons and is only carried out with Relevant Persons.


About MOLOGEN AG
MOLOGEN AG is a publicly listed biotechnology company headquartered in
Berlin and specializes in the research and clinical development of
innovative drugs in the fields of oncology and infectious diseases. One of
the company's most important product candidates is the DNA immunomodulator
MGN1703, which is being clinically developed for colorectal cancer and lung
cancer. The cell-based cancer therapy MGN1601 for the treatment of renal
cancer is also currently at the stage of clinical development.
With unique, patented technologies and innovative product developments,
MOLOGEN is one of the leading biotechnology companies in the fields of DNA
medicine and cell-based therapies.
MOLOGEN AG shares (ISIN DE0006637200) are listed in the Prime Standard of
the German Stock Exchange.
www.mologen.com


Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V.
| DECHEMA - Society for chemical technology and biotechnology e.V. |
German industrial association of biotechnology (DIB) | Association for
the Promotion of Science and Humanities in Germany | Association of